Table II.
Treatment outcome by ATM non-silent variant (ATM-NSV) status.
| Endpoint | Overall (n =73) | Not ATM-NSV (n =56) | ATM-NSV (n =17) | Odds/hazard ratio* | 95% CI* | p-Value* |
|---|---|---|---|---|---|---|
| Induction response, n (%) | ||||||
| Complete | 19 (26) | 15 (27) | 4 (24) | 0.84 | 0.24–2.99 | 0.79 |
| Partial | 47 (64) | 37 (66) | 10 (59) | |||
| None | 7 (10) | 4 (7) | 3 (18) | |||
| Overall response, n (%) | ||||||
| Complete | 33 (45) | 26 (46) | 7 (41) | 0.81 | 0.27–2.43 | 0.70 |
| Partial | 34 (47) | 26 (46) | 8 (47) | |||
| None | 6 (8) | 4 (7) | 2 (12) | |||
| Progression-free survival (PFS) | ||||||
| Median (months) | 42 | 42 | 35 | 1.23 | 0.67 –2.25 | 0.50 |
| PFS at 60 months, % (95% CI) | 33 (22 –44) | 35 (23 –48) | 25 (8 –48) | |||
| Overall survival (OS) | ||||||
| Median (months) | 91 | 91 | 91 | 0.91 | 0.46 –1.78 | 0.78 |
| OS at 60 months, % (95% CI) | 75 (64 –84) | 75 (61 –84) | 76 (49 –90) |
ATM, ataxia telangiectasia mutated.
*
Odds ratios, 95% confidence intervals (CIs) and p -values are provided for comparing presence of ATM-NSV versus absence of ATM-NSV with respect to achievement of complete remission using unadjusted logistic regression models; hazard ratios, 95% CIs and p -values are provided for comparing presence of ATM-NSV versus absence of ATM-NSV with respect to progression-free survival and overall survival using unadjusted proportional hazards models.